- Academic Editor
Background: Surgical treatment strategy for acute type A aortic
dissection (aTAAD) with mesenteric malperfusion (MMP) is quite challenging as it
is often associated with poor patient outcomes, and optimal management strategies
remain controversial. Methods: We conducted MEDLINE and EMBASE database
searches up to December 31, 2021 for studies on aTAAD with MMP. Data on study
design, patient demographics, patient management strategy, mortality,
complications, and follow-up were extracted, analyzed, and investigated.
Results: Our literature search identified 941 potentially relevant
studies, of which 19 were deemed eligible for this study. A total of 352
patients, mean age: 58.4
Acute type A aortic dissection (aTAAD) is the most severe of aortic disease
conditions and is associated with high mortality and morbidity. This condition
requires prompt surgical intervention to prevent death from aortic rupture. Organ
malperfusion is a catastrophic complication of aTAAD, and presents a great
challenge for both disease diagnosis and management. Mesenteric malperfusion
(MMP) secondary to aTAAD is a rare complication as it occurs in
Initial central repair of the ascending aorta in an attempt to restore adequate true lumenal flow can mitigate malperfusion syndromes and avoid aortic rupture. However, given the existence of distal re-entry tears, persistence of false lumen flow, and possibility of branch vessel involvement, the restoration of proximal true lumen inflow may not reliably improve poor distal malperfusion. In addition, cardiopulmonary bypass (CPB), with or without hypothermic circulatory arrest (HCA), is associated with significant attenuation of visceral blood flow and activation of inflammatory processes, and therefore it enhances ischemia or reperfusion injury. With the development of transcatheter techniques, many centers have adopted a strategy of endovascular repair followed by aortic, or simultaneous, repair to restore superior mesenteric artery (SMA) blood flow first in aTAAD patients with significant MMP [3, 4, 10]. Delayed central aortic repair provides patients an opportunity to recover from malperfusion syndrome, and improves outcomes in this setting. However, the risk of aortic rupture, or complicated acute aortic valve insufficiency are elevated. Currently, the optimal treatment strategy for patients with aTAAD complicated with MMP is still controversial with respect to both the technical mode of first-line intervention, specifically central aortic repair versus reperfusion of SMA, and the relative timing of these therapeutic strategies.
The objective of this study was to investigate the status of the clinical management of aTAAD with MMP, and assess current evidence regarding various treatment strategies for this severe condition with the goal of improving patient outcomes.
This systematic review was exempt from ethics approval as we collected and synthesized data published from previous studies in which informed consent had been obtained by the study investigators.
This review was non-registration protocol. It was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [11]. We searched MEDLINE through the PubMed portal and the EMBASE databases up to December 2021. Medical Subject Headings (MeSH) and text words were used for the searches and were supplemented by scanning the bibliographies of recovered articles.
The search strategy included a combination of keywords and MeSH including “mesenteric malperfusion”, “visceral malperfusion”, “organ malperfusion”, AND “acute type A aortic dissection”, “DeBakey Type I dissection”, “acute aortic dissection”. Two co-authors (CW and HW) reviewed and selected relevant articles independently for inclusion in this study. Differences of opinion between authors regarding included articles were resolved by consensus discussion. The references of selected articles were also reviewed to identify other potential articles for inclusion in this study.
Published studies were included if sufficient data regarding the number of patients who presented with aTAAD complicated with MMP, management strategies, and outcomes was provided. Only patients which MMP observed preoperatively were included. When registries or institutions published duplicate studies with extended length of follow-up or larger study populations, the latest and most complete study was included in this study to limit duplicate data. Case reports, reviews, and comments were excluded as well as reports that could not extract data precisely. Language was limited to articles written in English.
Data abstracted included various study characteristics such as study period, publication year, and institute, patient characteristics such as patient numbers, age, gender, and symptoms, the interval from onset of symptoms to operation (OSTO), and the first-line disease management strategy such as central aortic repair, reperfusion of SMA, exclusively endo-intervention, and exclusively medical intervention. Data abstracted also included surgical details such as the procedure conducted, cardiopulmonary bypass and cross clamp time, as well as in-hospital mortality and causes of death, postoperative complications, and patient follow-up.
We defined initial central aortic repair as the central surgery in initial treatment. Potential additional procedures included exploratory laparotomy, revascularization of SMA such as bypass, plasty, or stenting, as well as aortic stenting, fenestration, or thoracic endovascular aortic repair (TEVAR). We defined reperfusion of SMA as a first-line therapy as endovascular intervention, such as TEVAR, fenestration, or stenting, as well as bypass were often followed by or contemporaneous with central aortic repair surgery. Exclusively endo-intervention was defined as aortic or SMA stenting or fenestration, in which any other central surgical procedure was not performed. Exclusively medical intervention was defined as the patient receiving only medical care without any surgical or endovascular intervention.
The Cochrane’s Collaboration Risk of Bias Tool was used to assess the risk of bias at the study level, and categorize each study as high-risk, low-risk, or unclear-risk of bias [12].
Continuous variables were expressed as the mean
The literature search identified a total 929 studies (Fig. 1), and by manually retrieving the list of references, an additional 12 articles were identified. 68 papers were considered suitable for full text review after exclusion of duplicates or irrelevant studies. Nineteen studies were included in the final analysis [2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], which were all retrospective studies spanning a period from 1963 to 2019 (Table 1, Ref. [2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]).
Flow diagram illustrating the strategy used for identification, selection, and exclusion of articles used in this review. MMP, Mesenteric malperfusion.
First author | Study period | Published year | Institute | Study type | Total N. of patients | N. of SMA malperfusion patients (%) |
Koizumi S [13] | 2011–2019 | 2021 | Kobe City Medical Center General Hospital, Japan | Case series | 186 | 12 (6.4) |
Okita Y [3] | 1999–2017 | 2021 | Kobe University, Japan | Case series | 383 | 13 (3.4) |
Yamasaki M [14] | 2015–2017 | 2021 | Tokyo CCU Network Scientific Committee, Japan | Case series | 1504 | 14 (0.9) |
Iannacone E [15] | 1997–2019 | 2020 | Weill Cornell Medicine, USA | Case series | 336 | 7 (2.1) |
Sugiyama K [16] | 2017–2019 | 2020 | Aichi Medical University Hospital, Japan | Case series | 58 | 6 (10) |
Yang B [10] | 1996–2017 | 2019 | University of Michigan Hospital, USA | Case series | 602 | 82 (13.6) |
Leshnower BG [4] | 2003–2017 | 2019 | Emory University School of Medicine, USA | Case series | 618 | 34 (5.5) |
Kawahito K [17] | 1990–2016 | 2019 | Jichi Medical University School of Medicine, Japan | Case series | 1026 | 37 (3.6) |
Chiu P [18] | 2005–2015 | 2018 | Stanford Hospital, USA | Case series | 305 | 7 (2.3) |
Uchida K [19] | 2006–2016 | 2018 | Yokohama City University Medical Center, Japan | Case series | 438 | 12 (2.7) |
Yamashiro S [20] | 2000–2014 | 2015 | University of the Ryukyus, Japan | Case series | 121 | 10 (8.2) |
Pacinia D [21] | 2000–2008 | 2013 | The Emilia- Romagna Registry, Italy | Case series | 502 | 12 (2.4) |
Di Eusanio M [2] | 1995–2010 | 2013 | IRAD, 18 referral centers worldwide | Case series | 1809 | 68 (3.8) |
Girdauskas E [5] | 1994–2008 | 2009 | Heart Center Leipzig, Germany | Case series | 276 | 8 (3) |
Shiiya N [22] | 1991–2005 | 2007 | Hokkaido University Hospital, Japan | Case series | 84 | 5 (6) |
Geirsson A [23] | 1993–2004 | 2007 | University of Pennsylvania, USA | Case series | 221 | 3 (1.4) |
Yagdi T [6] | 1994–2003 | 2006 | Ege University Hospital, Turkey | Case series | 118 | 9 (7.6) |
Lauterbach SR [7] | 1990–1999 | 2001 | Massachusetts General Hospital | Case series | 101 | 5 (5) |
Farm JI [8] | 1963–1987 | 1990 | Stanford University Medical Center, USA | Case series | 128 | 8 (6.3) |
Total | 1963–2019 | 19 | 8816 | 352 (4) | ||
Notes: aTAAD, acute type A aortic dissection; SMA, superior mesenteric artery. |
A total of 352 patients diagnosed with aTAAD complicated with MMP were included
in this investigation. The incidence of MMP was 4% in aTAAD patients, and the
prevalence ranged from 0.9% [14] to 13.6% [10]. The median age of patients was
58.4
First author | N of patients | Age (years) | Sex (F) | Interval OSTO (hours) | Management Strategy | CCT (min) | CPB (min) | In-hospital mortality (%) | Causes of death | Postoperative Complications | Follow-up (mo) |
---|---|---|---|---|---|---|---|---|---|---|---|
Koizumi S [13] | 12 | 60 |
6 | NA | S1 | NA | NA | 2 (16.7%) | MOF (n = 1); rupture (n = 1) | resection of the bowel (n = 4), stroke (n = 2), acute renal injury (n = 2), re-sternotomy for bleeding (n = 1) | NA |
Okita Y [3] | 13 | 63.7 |
NA | 3.7 |
S1 (n = 8), S2 (n = 5) | NA | NA | 6 (46.2%) (4 in S1; 2 in S2) | Bowel necrosis (n = 6), MOF (n = 2) | resection of the bowel (n = 6) | Actuarial survival after surgery at 2 years was 33.3 |
Yamasaki M [14] | 14 | NA | NA | 3.9 | S1 | NA | NA | 2 (14.3) | NA | NA | NA |
Iannacone E [15] | 7 | NA | NA | NA | S1 | 90 (75–115) | 148 (131–172) | 2 (28.6%) | gangrenous bowel (n = 1); arresting (n = 1) | NA | NA |
Sugiyama K [16] | 6 | 58 (46–72) | 1 | NA | S1 (n = 2), S2 (n = 4) | NA | NA | 0 | 0 | paralytic ileus (n = 2), tracheostomy (n = 2) | NA |
Yang B [10] | 82 | 59.5 (50–68) | 22 | S2 | 156 (127–191) | 222 (185–261) | 32 (39%) | MOF (n = 22), rupture (n = 11) | Reoperation for bleeding (n = 5); Postoperative MI (n = 2); AF (n = 24); New-onset CVA (n = 3); New-onset paraplegia (n = 1); Pneumonia (n = 17); Tracheostomy (n = 14); dialysis (n = 1) | 10-year survival, 41% | |
Leshnower BG [4] | 34 | 53 |
8 | NA | S1 (n = 16), S2 (n = 13), S4 (n = 5) | 90, 131, 144, 178 | 151, 208, 214, 263 | 19 (55.8%) (9 in S1, 6 in S2, 4 in S4) | bowel necrosis (n = 13), died before op. (n = 3), protamine reaction (n = 1), stroke (n = 1), unknown (n = 1) | renal failure (n = 16), bowel necrosis or acidosis (n = 14) | NA |
Kawahito K [17] | 37 | NA | NA | S1 | NA | NA | 9 (24.3) | NA | NA | NA | |
Chiu P [18] | 7 | NA | NA | NA | S1 | NA | NA | 2 (28.6) | NA | NA | NA |
Uchida K [19] | 12 | NA | NA | NA | S1 (n = 5), S2 (n = 7) | NA | NA | 2 (16.7) (in S1) | bowel necrosis | NA | NA |
Yamashiro S [20] | 10 | 56.1 |
6 | 4.8 |
S1 (n = 2), S2 (n = 8) | 164.4 |
219.2 |
2 (20) (in S1) | MOF | NA | 115.8 |
Pacinia D [21] | 12 | NA | NA | NA | S1 | 99.0 |
185.2 |
8 (66.7) | NA | NA | survival rate of 10% at 5 years |
Di Eusanio M [2] | 68 | 61.8 |
21 | 19.1 (8.8–65.0) | S1 (n = 36), S3 (n = 11), S4 (n = 21) | NA | NA | 43 (63.2) (15 in S1, 8 in S3, 20 in S4) | visceral ischemia (n = 15), neurologic (n = 2), MOF (n = 5), cardiac (n = 2), tamponade (n = 2), not specified (n = 15) | Brain injury (n = 5), Spinal cord injury (n = 1), MI/ischemia (n = 4), Acute renal failure (n = 20), Limb ischemia (n = 5), Cardiac tamponade (n = 5) | NA |
Girdauskas E [5] | 8 | NA | NA | NA | S1 | NA | NA | 6 (75) | visceral ischemia | NA | 24 months |
Shiiya N [22] | 5 | 79, 42, 68, 55, 40 | 2 | NA | S1 | NA | NA | 0 | 0 | NA | NA |
Geirsson A [23] | 3 | NA | NA | NA | S1 | NA | NA | 1 (33.3) | MOF | no major complications | NA |
Yagdi T [6] | 9 | NA | NA | 36–48 | S1 | NA | NA | 9 (100) | bleeding, sepsis, or MOF | NA | no |
Lauterbach SR [7] | 5 | 59, 64, 87, 62, 48 | 1 | NA | S2 (n = 2), S4 (n = 3) | NA | NA | 4 (80) (1 in S2; 3 in S4) | Necrotic bowel or not specified | short-gut syndrome | NA |
Farm JI [8] | 8 | NA | NA | NA | S1 | NA | NA | 4 (50) | metabolic acidosis, myocardial failure, aortic rupture, renal failure, respiratory insufficiency | NA | NA |
Total | 352 | 58.4 |
M 159, F 70 | 39.9 |
S1 = 191, S2 = 121, S3 = 11, S4 = 29 | 153 (43.5%) | |||||
Notes: AF, atrial fibrillation; aTAAD, acute type A aortic dissection; CCT, cross-clamp time; CPB, cardiopulmonary bypass; CVA, cerebrovascular accident; NA, not available; OSTO, onset of symptoms to operation; MI, myocardial infarction; MOF, multiorgan failure; SMA, superior mesenteric artery; S1, Central aortic repair as first-line treatment; S2, Reperfusion of SMA as first-line treatment; S3, Exclusively endo-intervention; S4, Exclusively medical care. |
Overall, in-hospital mortality was 43.5% (n = 153), and ranged from 0 [16, 22] to 100% [6]. Bowel necrosis (43/153, 28.1%) and multiorgan failure (31/153, 20.3%) were the principal causes of death. The remaining causes of death included aortic rupture (12/153, 7.8%), neurologic complications (4/153, 2.6%), cardiac complications (including cardiac tamponade and arrest) (5/153, 3.3%), patient died before surgery (3/153, 2%), protamine reaction (1/153, 0.7%), and not specified (15/153, 9.8%). 38 patients did not have a documented cause of death.
5 studies reported patient follow-up. One study included 13 patients where the
2-year survival after surgery was 33.3
Postoperative complications were partially documented across the included studies. Complications included postoperative bowel necrosis that required resection of the bowel or acidosis (n = 24), acute renal injury (n = 39), postoperative atrial fibrillation (n = 24), and pneumonia (n = 17) were reported. Other comorbidities included stroke, re-sternotomy for bleeding, tamponade, postoperative myocardial infarction, new-onset paraplegia, and paralytic ileus. Eleven studies which included a total of 129 patients did not document postoperative complications.
A variety of treatment strategies for aTAAD complicated with MMP were encountered during this investigation. The first-line management strategies were classified as one of four types; specifically, central aortic repair (191, 54.3%), reperfusion of SMA (121, 34.3%), exclusively endo-intervention (11, 3.1%) and exclusively medical intervention (29, 8.2%) (Table 3).
Death | Strategy | Total | |||
Central repair-first | Reperfusion of SMA-first | Exclusively endo-intervention | Exclusively medical care | ||
Survival | 114 (59.7%) | 80 (66.1%) | 3 (27.3%) | 2 (6.9%) | 199 |
Death | 77 (40.3%) | 41 (33.9%) | 8 (72.7%) | 27 (93.1%) | 153 |
Total | 191 | 121 | 11 | 29 | 352 |
Chi-Square Tests, Central aortic repair as first therapy vs. reperfusion of SMA as first therapy Central aortic repair as first therapy vs. exclusively endo-intervention Central aortic repair as first therapy vs. exclusively medical care Reperfusion of SMA as first therapy vs. exclusively endo-intervention Reperfusion of SMA as first therapy vs. exclusively medical care Exclusively endo-intervention vs. exclusively medical care Notes: aTAAD, acute type A aortic dissection; SMA, superior mesenteric artery. |
In-hospital mortality was 40.3% (77 of 191) and 33.9% (41 of 121) in patients
with first-line therapy of central aortic repair or reperfusion of SMA,
respectively. This difference was found to be not statistically significant
(
The exact causes of death, postoperative complications and survival rates of
each group were not extracted. The details of the central aortic repair procedure
including choice of arterial cannulation, core temperature during hypothermic
circulatory arrest (HCA), cerebral perfusion strategy, HCA time, cross-clamp
time, and CPB time were missing in most of the included studies. From this
investigation, the interval from onset of symptoms to operation was 39.9
aTAAD complicated with MMP remains clinically challenging, commonly has poor outcomes, and optimal management practices are controversial. In this systematic review of 352 cases, the prevalence of MMP in aTAAD patients was low at 4%, but the pooled in-hospital mortality rate was very high at 43.5%. Five studies reported mortality rates greater than 50%, such as the study by Yagdi et al. [6], which reported an in-hospital mortality rate of 100%. However, this was a small cohort of 9 patients, and the majority of the deaths were bleeding, sepsis, or multiple organ failure. In contrast, some of the included studies reported lower mortality rates, for example, two studies Sugiyama et al. [16] and Shiiya et al. [22] reported in-hospital mortality rates of 0%. Both studies were comprised of a smaller cohort of patients and included only 5 and 6 patients, respectively.
As the two major surgical strategies for treatment of aTAAD with MMP, the survival of patients receiving central aortic repair first versus reperfusion of SMA was notably higher compared with conservative medical treatment (59.7%, 66.1% vs. 6.9%). In retrospect this makes surgical treatment superior to conservative medical treatment options.
Open surgical repair of the ascending aorta is a life-saving operation and remains the standard of care for patients with aTAAD, but is associated with a high rate of mortality in patients with MMP [2, 24, 25]. A long central repair surgery, with the patient on cardiopulmonary bypass with circulatory arrest, may accelerate ongoing intestinal ischemia and result in poor outcomes. In this review, the in-hospital mortality of central aortic repair as first treatment strategy was 40.3%, and this was found to be greater than reperfusion of SMA as the first strategy (34.3%). However, there was no significant difference in patient survival between these two approaches. This result is similar to several previous studies [2, 3, 4, 19, 20] which reported the in-hospital mortality of the reperfusion first strategy was lower than that of traditional central aortic repair first strategies. Mesenteric malperfusion time plays a role in determining outcomes in aTAAD patients, and expeditious reperfusion of SMA was crucial for favorable outcome. As a minimally invasive approach, percutaneous endovascular technique can quickly restore adequate blood flow to the obstructed arteries. The reperfusion as first treatment strategy is being gradually adopted as an alternative treatment option for aTAAD with MMP. This approach provides borderline patients the opportunity to recover and improve both short and long-term survival, as well as preventing a futile open aortic repair in the presence of unsalvageable organ damage and failure [26].
The premise of the reperfusion as first therapeutic strategy is possible in hemodynamically stable patients. However, hemodynamic instability is an important predictive factor for post-operative mortality in open surgical repair of the ascending aorta [25, 27]. Undoubtedly, patients with evidence of aortic rupture or cardiac tamponade who undergo central aortic repair contribute to the mortality rate of the central aortic repair as first therapy strategy patients. Of note, delaying open aortic repair in the treatment of aTAAD is controversial, and risks aortic rupture. For example, in the study by Yang et al. [10], the investigators reported eleven patients (13% of the study cohort) died from aortic rupture before receiving aortic repair surgery.
The period of medical stabilization from reperfusion of SMA to proximal aortic surgery is critical in weighing the risk of aortic rupture and inflammatory responses associated with CPB and adjunctive HCA and several authors have advocated for a strategy of simultaneous surgery [28, 29, 30]. A hybrid operating room [31] might address the reperfusion of vessel ischemia as first therapy followed by contemporaneous central aorta repair. Hybrid operating room (Hybrid OR) represents the ideal environment for teamwork between cardiovascular surgeon, vascular interventionist, and cardiac anesthesiologist. This concept offers a multidisciplinary opportunity for enhanced treatment of aTAAD with MMP. At present, there are no randomized studies on central aortic repair as the first treatment approach versus reperfusion of SMA, thus, and an individualized approach is essential. The American Association for Thoracic Surgery expert consensus document recommends it is reasonable to delay proximal aortic repair until after definitive treatment of mesenteric malperfusion (IIa, B) [24].
In IRAD, patients with MMP were less likely to undergo surgical treatment and more likely to receive medical or endovascular therapy [2]. As a treatment strategy, exclusively endo-intervention had a mortality rate of 72.7% and we measured a statistically significant difference when compared with an intervention of reperfusion of SMA as first therapy followed by central aortic repair. Exclusively medical therapy was associated with a dismal mortality rate (93.1%). Our study leads us to conclude that conventional central aorta repair as a standard treatment of aTAAD is essential.
An accurate diagnosis of MMP in aTAAD remains challenging. Only 60% of patients present with abdominal pain and no laboratory study can definitively confirm the presence, or absence, of mesenteric malperfusion [2]. Approximately 20% of patients without mesenteric malperfusion exhibited pain confirming that abdominal pain is a nonspecific symptom of acute mesenteric ischemia and, consequently, the diagnosis of MMP is frequently made too late to save the bowel and the patient [2, 25]. In this investigation, the time from onset of symptoms to operation varies greatly among the studies, and most studies do not record this time, thus, the optimal cutoff time on surgical intervention remains unclear. Accurate and timely diagnosis of MMP and prompt surgical intervention to restore the reperfusion of SMA might improve the poor outcomes. Hence, clinical investigation of data linking the onset of symptoms to surgery and corresponding outcomes are needed.
There are several significant limitations to consider when interpreting the results described in this study. Being a retrospective systematic review on management of aTAAD complicated with MMP, the data has inherent deficiencies. The risk of publication bias appears inevitable due to small samples in most studies, as well as the absence of preoperative clinical data and loss of patient follow-up. This may represent a number of different factors, such as different patient population or selection, differing centers with varying operator experience, or the different strategies used across the included studies. There were also variations in diagnosis of mesenteric malperfusion at different centers. Given these limitations, a general conclusion based on a solid statistical analysis with adequate sample sizes is not presently possible.
The available literature on aTAAD with MMP shows that aTAAD with MMP is a rare complication carrying a higher in-hospital mortality. Central aortic repair and reperfusion of SMA as the first therapeutic approaches appear to be associated with better outcomes compared with exclusively endo-intervention or medical management. Clinical decisions may have introduced biases showing no differences on the way patients were being prioritized regarding central aortic repair and reperfusion of SMA as the first therapy. With respect to the variation in presentation and pathology, an individualized approach is recommended.
aTAAD, Acute type A aortic dissection; MMP, Mesenteric malperfusion; SMA, Superior mesenteric artery; TEVAR, Thoracic endovascular aortic repair.
Data underlying the systematic review are retrieved from published studies and hence already available in literature; no unpublished data were employed. However, the collected data underlying this article will be shared on reasonable request to the corresponding author.
CW and HW designed the research study. CW performed the research. CW, HW, ZX, QL, LS, LZ provided data collection, critical revision of the article. CW analyzed the data. CW, HW, ZX, QL, LS, LZ wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
Not applicable.
Not applicable.
This research received no external funding.
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.